CureVac partners with Bayer for COVID-19 vaccine deal.
CureVac has recently agreed to an alliance with Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and support for vaccine distribution.
Under the terms of the alliance agreement, Bayer will be responsible for providing access to international pharmaceutical markets as well as its global supply chain and distribution network. No financial terms were disclosed.
Last month, CureVac began its large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the vaccine development race for the novel COVID-19.
Moderna’s CEO says vaccine immunization likely to last for a couple of years.
According to Moderna’s Chief Executive Officer, their COVID-19 mRNA vaccine is likely to offer protection of up to a couple of years, although more data is still needed to make a definitive assessment.
Moderna who led the vaccine race against the novel COVID-19 was able to receive approval for its vaccines in just a few weeks from the European Commission.
He added that Moderna will also investigate the vaccine’s efficacy against the new variant of COVID-19 which was recently seen in the United Kingdom and South Africa.
South Africa purchases 1.5 million doses of the AstraZeneca COVID-19 vaccine.
South Africa recently announced that they will be purchasing 1.5 million doses of AstraZeneca’s COVID-19 vaccine.
The first 1 million doses will be delivered in the latter part of January from the Serum Institute of India, followed by an additional 500,000 doses in February.
South Africa is currently experiencing a resurgence of COVID-19 cases with a record high of 21,832 new confirmed cases last week.
The country of 60 million people has reported by far the most cases of the coronavirus in Africa, with more than 1.1 million confirmed infections, including 31,368 deaths, representing more than 30% of all cases on the continent of 1.3 billion.